Obinutuzumab in Primary MN

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Membranous Nephropathy
Interventions
DRUG

Obinutuzumab

Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.

Trial Locations (2)

24020

"Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò", Ranica

24100

ASST HPG23 - Unità di Nefrologia, Bergamo

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Mario Negri Institute for Pharmacological Research

OTHER